The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Luka Milas

Department of Experimental Radiation Oncology

University of Texas M. D. Anderson Cancer Center

Houston 77030

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. 2000 - 2009

References

  1. Cancer stem cells and tumor response to therapy: current problems and future prospects. Milas, L., Hittelman, W.N. Semin. Radiat. Oncol (2009) [Pubmed]
  2. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Milas, L., Fang, F.M., Mason, K.A., Valdecanas, D., Hunter, N., Koto, M., Ang, K.K. Int. J. Radiat. Oncol. Biol. Phys. (2007) [Pubmed]
  3. Targeting molecular determinants of tumor chemo-radioresistance. Milas, L., Raju, U., Liao, Z., Ajani, J. Semin. Oncol. (2005) [Pubmed]
  4. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Milas, L., Fan, Z., Andratschke, N.H., Ang, K.K. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  5. CpG oligodeoxynucleotide enhances tumor response to radiation. Milas, L., Mason, K.A., Ariga, H., Hunter, N., Neal, R., Valdecanas, D., Krieg, A.M., Whisnant, J.K. Cancer Res. (2004) [Pubmed]
  6. Chemoradiotherapy: emerging treatment improvement strategies. Milas, L., Mason, K.A., Liao, Z., Ang, K.K. Head. Neck (2003) [Pubmed]
  7. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Milas, L., Mason, K.A., Hunter, N., Li, C., Wallace, S. Int. J. Radiat. Oncol. Biol. Phys. (2003) [Pubmed]
  8. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Milas, L., Mason, K.A., Crane, C.H., Liao, Z., Masferrer, J. Oncology (Williston Park, N.Y.) (2003) [Pubmed]
  9. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Milas, L., Akimoto, T., Hunter, N.R., Mason, K.A., Buchmiller, L., Yamakawa, M., Muramatsu, H., Ang, K.K. Int. J. Radiat. Oncol. Biol. Phys. (2002) [Pubmed]
  10. Docetaxel/radiation combinations: rationale and preclinical findings. Milas, L. Clin. Lung. Cancer (2002) [Pubmed]
  11. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, J., Fan, Z. Clin. Cancer Res. (2000) [Pubmed]
 
WikiGenes - Universities